Anna Rivera/LinkedIn
Jun 2, 2026, 17:55
Anna Rivera: Hemophilia Management – A Shift from Traditional IV Therapies to Novel Subcutaneous Agents
Anna Rivera, Director of Operations at Rx Relief, shared a post on LinkedIn:
“Hemophilia management is undergoing a shift from traditional IV therapies to novel subcutaneous agents.
As these advanced therapies emerge, the clinical pharmacist’s role in protocol development and patient education is vital.”
Stay updated with Hemostasis today.
-
Jun 2, 2026, 17:53Zoya Surayya: My Thesis on Anticoagulation After Ischemic Stroke
-
Jun 2, 2026, 17:49Jeffrey Hall: A Pivotal Moment to Protect Rhode Island Wildlife from Anticoagulant Rodenticides
-
Jun 2, 2026, 17:47Nathan Connell: Connecting History with the Future of VWD Care
-
Jun 2, 2026, 17:38Arun V. J: The Most Racist Cell In The Human Body is The Red Blood Cell
-
Jun 2, 2026, 17:34Leonard Valentino: How We Protect Joints in People With Hemophilia
-
Jun 2, 2026, 17:26Puvaneswaran Akash: Emergency Management of Acute Myocardial Infarction
-
Jun 2, 2026, 15:28Kabilan K. L.: Management and Diagnosis of Acute Coronary Syndrome Types
-
Jun 2, 2026, 15:26Mital Jhaveri: What New Data Reveal About DOACs and Androgen Receptor Inhibitors?
-
Jun 2, 2026, 15:22Dhananjaya Kotebagilu Narayana Vamyanmane: High-Resolution Ultrasound Evaluation of Bowel Wall Ischemia